- Home
- ENTX vs IKNA Comparison
ENTX vs IKNA Comparison
Compare ENTX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- IKNA
- Stock Information
- Founded
- ENTX 2010
- IKNA 2016
- Country
- ENTX Israel
- IKNA United States
- Employees
- ENTX N/A
- IKNA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- IKNA Health Care
- Exchange
- ENTX Nasdaq
- IKNA Nasdaq
- Market Cap
- ENTX 60.7M
- IKNA 78.7M
- IPO Year
- ENTX 2018
- IKNA 2021
- Fundamental
- Price
- ENTX $1.79
- IKNA $1.69
- Analyst Decision
- ENTX Strong Buy
- IKNA Buy
- Analyst Count
- ENTX 1
- IKNA 2
- Target Price
- ENTX $10.00
- IKNA $3.00
- AVG Volume (30 Days)
- ENTX 36.8K
- IKNA 75.2K
- Earning Date
- ENTX 08-09-2024
- IKNA 08-08-2024
- Dividend Yield
- ENTX N/A
- IKNA N/A
- EPS Growth
- ENTX N/A
- IKNA N/A
- EPS
- ENTX N/A
- IKNA N/A
- Revenue
- ENTX $57,000.00
- IKNA $1,844,000.00
- Revenue This Year
- ENTX N/A
- IKNA N/A
- Revenue Next Year
- ENTX N/A
- IKNA N/A
- P/E Ratio
- ENTX N/A
- IKNA N/A
- Revenue Growth
- ENTX 159.09
- IKNA N/A
- 52 Week Low
- ENTX $0.52
- IKNA $1.02
- 52 Week High
- ENTX $3.35
- IKNA $4.95
- Technical
- Relative Strength Index (RSI)
- ENTX 52.71
- IKNA 49.56
- Support Level
- ENTX $1.62
- IKNA $1.66
- Resistance Level
- ENTX $2.03
- IKNA $1.87
- Average True Range (ATR)
- ENTX 0.12
- IKNA 0.05
- MACD
- ENTX 0.03
- IKNA -0.01
- Stochastic Oscillator
- ENTX 42.86
- IKNA 14.29
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.